Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

Johnson & Johnson’s inflammatory diseases blockbuster Remicade (infliximab) faces further US competition after the FDA granted a licence for Samsung Bioepis’ biosimilar, Renflexis, in all the ...